See more : VAT Group AG (VACNY) Income Statement Analysis – Financial Results
Complete financial analysis of BioCardia, Inc. (BCDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioCardia, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FUJIFILM Holdings Corporation (4901.T) Income Statement Analysis – Financial Results
- CANbridge Pharmaceuticals Inc. (1228.HK) Income Statement Analysis – Financial Results
- Technocraft Industries (India) Limited (TIIL.BO) Income Statement Analysis – Financial Results
- Tern Plc (TERN.L) Income Statement Analysis – Financial Results
- Dosilicon Co., Ltd. (688110.SS) Income Statement Analysis – Financial Results
BioCardia, Inc. (BCDA)
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477.00K | 1.35M | 1.02M | 145.00K | 710.00K | 625.00K | 479.00K | 576.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.87M | 1.27M | 643.00K | 0.00 | 0.00 | 0.00 | 3.76M | 4.08M | 3.96M | 3.87M | 3.99M | 4.20M | 3.80M | 3.40M | 3.15M |
| Cost of Revenue | 7.73M | 11.90M | 640.00K | 4.00K | 358.00K | 517.00K | 690.00K | 746.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 380.00K | 197.00K | 130.00K | 0.00 | 0.00 | 0.00 | 860.33K | 1.01M | 971.26K | 952.26K | 898.17K | 1.00M | 900.00K | 800.00K | 727.61K |
| Gross Profit | -7.25M | -10.55M | 375.00K | 141.00K | 352.00K | 108.00K | -211.00K | -170.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.49M | 1.07M | 513.00K | 0.00 | 0.00 | 0.00 | 2.90M | 3.07M | 2.99M | 2.91M | 3.09M | 3.20M | 2.90M | 2.60M | 2.42M |
| Gross Profit Ratio | -1,519.71% | -780.25% | 36.95% | 97.24% | 49.58% | 17.28% | -44.05% | -29.51% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 79.67% | 84.46% | 79.78% | 0.00% | 0.00% | 0.00% | 77.12% | 75.32% | 75.46% | 75.37% | 77.48% | 76.19% | 76.32% | 76.47% | 76.89% |
| Research & Development | 7.73M | 8.83M | 8.56M | 9.81M | 8.56M | 8.45M | 5.80M | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 1.33M | 215.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73M | 0.00 | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.40M | 4.42M | 5.09M | 5.86M | 6.00M | 5.76M | 6.40M | 4.11M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 5.59M | 3.91M | 610.00K | 79.80K | 98.18K | 101.48K | 3.59M | 3.58M | 4.14M | 4.93M | 4.90M | 4.30M | 4.00M | 3.20M | 2.21M |
| Other Expenses | 0.00 | -6.00K | -2.00K | -2.00K | -2.00K | -3.00K | 2.00K | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.37K | 0.00 | 85.72K | 0.00 | 0.00 | 0.00 | 115.45K | 100.00K | 100.00K | 100.00K | 0.00 |
| Operating Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.57M | 14.21M | 12.19M | 7.44M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.59M | 5.25M | 825.00K | 79.80K | 92.80K | 101.48K | 3.68M | 3.58M | 4.14M | 4.93M | 5.02M | 4.40M | 4.10M | 3.30M | 2.21M |
| Cost & Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.92M | 14.73M | 12.88M | 8.18M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.97M | 5.44M | 955.00K | 79.80K | 92.80K | 101.48K | 4.54M | 4.58M | 5.11M | 5.88M | 5.91M | 5.40M | 5.00M | 4.10M | 2.94M |
| Interest Income | 0.00 | 0.00 | 9.00K | 21.00K | 87.00K | 118.00K | 95.00K | 0.00 | 3.00K | 3.00K | 10.00K | 8.00K | 11.00K | 0.00 | 0.00 | 0.00 | 33.00K | 4.36K | 5.37K | 1.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.00K | 0.00 | 3.00K | 112.00K | 0.00 | 95.00K | 1.74M | 3.00K | 3.00K | 10.00K | 8.00K | 25.00K | 27.00K | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.00K |
| Depreciation & Amortization | 84.00K | 377.00K | 640.00K | 566.00K | 551.00K | 203.00K | 78.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 967.00K | 1.21M | 561.00K | 61.00K | 0.00 | 0.00 | 0.00 | 71.08K | 84.93K | 101.83K | 107.91K | 115.45K | 100.00K | 100.00K | 100.00K | 49.74K |
| EBITDA | -11.56M | -11.82M | -12.57M | -14.44M | -14.05M | -13.90M | -12.23M | -8.54M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | 384.00K | -3.90M | -3.61M | -218.00K | -79.80K | -92.80K | -101.48K | -99.79K | -443.03K | -418.80K | -1.05M | -1.91M | -1.81M | -1.10M | -1.00M | -600.00K |
| EBITDA Ratio | -2,423.48% | -880.25% | -1,237.73% | -10,649.66% | -1,974.23% | -2,223.84% | -2,573.49% | -1,146.70% | 61.70% | 54.10% | 3.36% | -546.77% | -5,058.33% | 0.00% | -208.40% | -170.11% | -33.90% | 0.00% | 0.00% | 0.00% | -18.08% | -10.86% | -24.66% | -50.88% | -54.95% | -23.81% | -42.11% | -17.65% | 9.25% |
| Operating Income | -11.64M | -11.90M | -12.63M | -15.53M | -14.21M | -14.10M | -12.41M | -7.61M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | -583.00K | -5.10M | -5.63M | -312.00K | -79.80K | -92.80K | -101.48K | -779.68K | -503.74K | -1.15M | -2.02M | -1.93M | -1.20M | -1.20M | -700.00K | 206.23K |
| Operating Income Ratio | -2,441.09% | -880.25% | -1,244.33% | -10,709.66% | -2,001.83% | -2,256.32% | -2,589.77% | -1,320.83% | 61.70% | 54.10% | 3.36% | -546.77% | -5,150.00% | 0.00% | -272.98% | -444.16% | -48.52% | 0.00% | 0.00% | 0.00% | -20.74% | -12.35% | -29.13% | -52.20% | -48.28% | -28.57% | -31.58% | -20.59% | 6.55% |
| Total Other Income/Expenses | 73.00K | -6.00K | 7.00K | 525.00K | -496.00K | 115.00K | 97.00K | -2.70M | 3.00K | 3.00K | 10.00K | 8.00K | -14.00K | 27.00K | 24.00K | -20.00K | 33.00K | -199.20K | 0.00 | 0.00 | 679.90K | 24.23K | 24.23K | 56.84K | 56.84K | 625.51K | 500.00K | 0.00 | 839.12K |
| Income Before Tax | -11.57M | -11.91M | -12.62M | -15.00M | -14.71M | -13.99M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | -331.00K | -632.00K | -556.00K | -5.08M | -5.80M | -279.00K | 0.00 | 0.00 | 0.00 | -722.70K | -479.51K | -1.23M | -1.96M | -1.54M | -1.30M | -700.00K | 0.00 | 139.12K |
| Income Before Tax Ratio | -2,425.79% | -880.70% | -1,243.65% | -10,347.59% | -2,071.69% | -2,237.92% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | -533.87% | -5,266.67% | 0.00% | -271.70% | -457.41% | -43.39% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -50.73% | -38.72% | -30.95% | -18.42% | 0.00% | 4.42% |
| Income Tax Expense | 0.00 | 6.00K | -2.00K | 1.00K | 110.00K | -115.00K | -192.00K | 5.40M | -6.00K | -6.00K | -20.00K | -652.00K | -10.31M | 10.90M | -48.00K | 3.10M | 0.00 | -4.36K | 92.80K | 710.86K | -28.24K | -48.45K | 149.87K | 103.91K | -762.83K | 200.00K | -1.10M | -100.00K | 3.53K |
| Net Income | -11.57M | -11.91M | -12.62M | -15.01M | -14.82M | -13.87M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | 305.00K | 9.66M | -11.51M | -5.08M | -5.80M | -287.00K | -75.44K | -92.80K | -812.34K | -722.70K | -479.51K | -1.23M | -2.18M | -1.54M | -1.30M | -600.00K | -600.00K | 135.60K |
| Net Income Ratio | -2,425.79% | -881.14% | -1,243.45% | -10,348.28% | -2,087.18% | -2,219.52% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | 491.94% | 80,516.67% | 0.00% | -271.70% | -457.41% | -44.63% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -56.35% | -38.72% | -30.95% | -15.79% | -17.65% | 4.31% |
| EPS | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.91 | -275.16 | -237.12 | -210.36 | -97.17 | -117.32 | 0.38 |
| EPS Diluted | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.15 | -275.16 | -237.12 | -204.63 | -97.17 | -113.64 | 0.38 |
| Weighted Avg Shares Out | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.82K | 7.92K | 6.51K | 6.18K | 6.18K | 5.11K | 360.60K |
| Weighted Avg Shares Out (Dil) | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.86K | 7.92K | 6.51K | 6.35K | 6.18K | 5.28K | 360.60K |
BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair...
BioCardia Letter to Shareholders
SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders:
BioCardia Announces $3.6 Million Private Placement of Common Stock
SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration...
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
SUNNYVALE, Calif.--(BUSINESS WIRE)--BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to initiate a first-in-human...
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
SUNNYVALE, Calif.--( BUSINESS WIRE )--BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to initiate...
BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright...
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly...
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know
BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months...
Source: https://incomestatements.info
Category: Stock Reports